1
|
Lee YS, Bang YJ, Yoo S, Park SI, Park HJ, Kwak HW, Bae SH, Park HJ, Kim JY, Youn SB, Roh G, Lee S, Kwon SP, Bang EK, Keum G, Nam JH, Hong SH. Analysis of the Immunostimulatory Effects of Cytokine-Expressing Internal Ribosome Entry Site-Based RNA Adjuvants and Their Applications. J Infect Dis 2024; 229:1408-1418. [PMID: 37711050 DOI: 10.1093/infdis/jiad392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 09/01/2023] [Accepted: 09/12/2023] [Indexed: 09/16/2023] Open
Abstract
Developing new adjuvants that can effectively induce humoral and cellular immune responses while broadening the immune response is of great value. In this study, we aimed to develop single-stranded RNA adjuvants expressing (1) granulocyte monocyte colony-stimulating factor or (2) interleukin 18 based on the encephalomyocarditis virus internal ribosome entry site; we also tested their efficacy in combination with ovalbumin or inactivated influenza vaccines. Notably, cytokine-expressing RNA adjuvants increased the expression of antigen-presenting cell activation markers in mice. Specifically, when combined with ovalbumin, RNA adjuvants expressing granulocyte monocyte colony-stimulating factor increased CD4+ T-cell responses, while those expressing interleukin 18 increased CD8+ T-cell responses. Cytokine-expressing RNA adjuvants further increased the frequency of polyclonal T cells with the influenza vaccine and reduced the clinical illness scores and weight loss of mice after viral challenge. Collectively, our results suggest that cytokine-expressing RNA adjuvants can be applied to protein-based or inactivated vaccines to increase their efficacy.
Collapse
Affiliation(s)
- Yu-Sun Lee
- Department of Biotechnology
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
| | - Yoo-Jin Bang
- Department of Biotechnology
- Central Research Institute, SML Biopharm, Gwangmyeong
| | - Soyeon Yoo
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul
| | - Sang-In Park
- Central Research Institute, SML Biopharm, Gwangmyeong
| | - Hyo-Jung Park
- Department of Biotechnology
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
| | - Hye Won Kwak
- Central Research Institute, SML Biopharm, Gwangmyeong
| | - Seo-Hyeon Bae
- Department of Biotechnology
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
| | | | - Jae-Yong Kim
- Department of Biotechnology
- Central Research Institute, SML Biopharm, Gwangmyeong
| | - Sue-Bean Youn
- Department of Biotechnology
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
| | - Gahyun Roh
- Department of Biotechnology
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
| | - Seonghyun Lee
- Department of Biotechnology
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
| | - Sung Pil Kwon
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul
| | - Eun-Kyoung Bang
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul
| | - Gyochang Keum
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul
| | - Jae-Hwan Nam
- BK21 FOUR Department of Biotechnology, The Catholic University of Korea, Bucheon
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon
| | - So-Hee Hong
- Department of Microbiology, College of Medicine, Ewha Womans University, Seoul, Republic of Korea
| |
Collapse
|
2
|
Lee S, Yoon H, Hong SH, Kwon SP, Hong JJ, Kwak HW, Park HJ, Yoo S, Bae SH, Park HJ, Lee J, Bang YJ, Lee YS, Kim JY, Yoon S, Roh G, Cho Y, Kim Y, Kim D, Park SI, Kim DH, Lee S, Oh A, Ha D, Lee SY, Park M, Hwang EH, Bae G, Jeon E, Park SH, Choi WS, Oh HR, Kim IW, Youn H, Keum G, Bang EK, Rhee JH, Lee SE, Nam JH. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization. J Med Virol 2023; 95:e29309. [PMID: 38100632 DOI: 10.1002/jmv.29309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 11/25/2023] [Accepted: 11/27/2023] [Indexed: 12/17/2023]
Abstract
The E6 and E7 proteins of specific subtypes of human papillomavirus (HPV), including HPV 16 and 18, are highly associated with cervical cancer as they modulate cell cycle regulation. The aim of this study was to investigate the potential antitumor effects of a messenger RNA-HPV therapeutic vaccine (mHTV) containing nononcogenic E6 and E7 proteins. To achieve this, C57BL/6j mice were injected with the vaccine via both intramuscular and subcutaneous routes, and the resulting effects were evaluated. mHTV immunization markedly induced robust T cell-mediated immune responses and significantly suppressed tumor growth in both subcutaneous and orthotopic tumor-implanted mouse model, with a significant infiltration of immune cells into tumor tissues. Tumor retransplantation at day 62 postprimary vaccination completely halted progression in all mHTV-treated mice. Furthermore, tumor expansion was significantly reduced upon TC-1 transplantation 160 days after the last immunization. Immunization of rhesus monkeys with mHTV elicited promising immune responses. The immunogenicity of mHTV in nonhuman primates provides strong evidence for clinical application against HPV-related cancers in humans. All data suggest that mHTV can be used as both a therapeutic and prophylactic vaccine.
Collapse
Affiliation(s)
- Seonghyun Lee
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Hyunho Yoon
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Seol Hee Hong
- National Immunotherapy Innovation Center, Hwasun-gun, Jeonnam, South Korea
- Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, South Korea
| | - Sung Pil Kwon
- Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea
| | - Jung Joo Hong
- National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea
- KRIBB School of Bioscience, Korea University of Science & Technology (UST), Daejeon, South Korea
| | - Hye Won Kwak
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Hyeong-Jun Park
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Soyeon Yoo
- Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea
| | - Seo-Hyeon Bae
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Hyo-Jung Park
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Jisun Lee
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Yoo-Jin Bang
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Yu-Sun Lee
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Jae-Yong Kim
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Subin Yoon
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Gahyun Roh
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Youngran Cho
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Yongkwan Kim
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Daegeun Kim
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Sang-In Park
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Do-Hyung Kim
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- R&D Research Center, SML Biopharm, Gwangmyeong, Gyeonggi-do, South Korea
| | - Sowon Lee
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Ayoung Oh
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Dahyeon Ha
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Soo-Yeon Lee
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Misung Park
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| | - Eun-Ha Hwang
- National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea
| | - Gyuseo Bae
- National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea
| | - Eunsu Jeon
- National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea
| | - Sung Hyun Park
- National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea
| | - Won Seok Choi
- National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Chungcheongbuk-do, South Korea
| | - Ho Rim Oh
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - In Woo Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
| | - Hyewon Youn
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea
- Department of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul, South Korea
| | - Gyochang Keum
- Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea
| | - Eun-Kyoung Bang
- Brain Science Institute, Korea Institute of Science and Technology, Seoul, South Korea
| | - Joon Haeng Rhee
- Department of Microbiology, Chonnam National University Medical School, Hwasun-gun, Jeonnam, South Korea
| | - Shee Eun Lee
- National Immunotherapy Innovation Center, Hwasun-gun, Jeonnam, South Korea
- Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju, South Korea
| | - Jae-Hwan Nam
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
- BK21 four Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, South Korea
| |
Collapse
|
3
|
Park HJ, Bang YJ, Kwon SP, Kwak W, Park SI, Roh G, Bae SH, Kim JY, Kwak HW, Kim Y, Yoo S, Kim D, Keum G, Bang EK, Hong SH, Nam JH. Analyzing immune responses to varied mRNA and protein vaccine sequences. NPJ Vaccines 2023; 8:84. [PMID: 37271785 DOI: 10.1038/s41541-023-00684-0] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Accepted: 05/25/2023] [Indexed: 06/06/2023] Open
Abstract
In response to the COVID-19 pandemic, different types of vaccines, such as inactive, live-attenuated, messenger RNA (mRNA), and protein subunit, have been developed against SARS-CoV-2. This has unintentionally created a unique scenario where heterologous prime-boost vaccination against a single virus has been administered to a large human population. Here, we aimed to analyze whether the immunization order of vaccine types influences the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines. We developed a new mRNA vaccine encoding the hemagglutinin (HA) glycoprotein of the influenza virus using the 3'-UTR and 5'-UTR of muscle cells (mRNA-HA) and tested its efficacy by heterologous immunization with an HA protein vaccine (protein-HA). The results demonstrated higher IgG2a levels and hemagglutination inhibition titers in the mRNA-HA priming/protein-HA boosting (R-P) regimen than those induced by reverse immunization (protein-HA priming/mRNA-HA boosting, P-R). After the viral challenge, the R-P group showed lower virus loads and less inflammation in the lungs than the P-R group did. Transcriptome analysis revealed that the heterologous prime-boost groups had differentially activated immune response pathways, according to the order of immunization. In summary, our results demonstrate that the sequence of vaccination is critical to direct desired immune responses. This study demonstrates the potential of a heterologous vaccination strategy using mRNA and protein vaccine platforms against viral infection.
Collapse
Affiliation(s)
- Hyeong-Jun Park
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
- BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Yoo-Jin Bang
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
- BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Sung Pil Kwon
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea
| | - Woori Kwak
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
| | - Sang-In Park
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Gahyun Roh
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
- BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea
| | - Seo-Hyeon Bae
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
- BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea
| | - Jae-Yong Kim
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea
- BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Hye Won Kwak
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Yongkwan Kim
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Soyeon Yoo
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea
| | - Daegeun Kim
- SML Biopharm, Gwangmyeong, 14353, Republic of Korea
| | - Gyochang Keum
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea
| | - Eun-Kyoung Bang
- Center for Brain Technology, Brain Science Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
| | - So-Hee Hong
- Department of Microbiology, College of Medicine, Ewha Womans University, Seoul, 07804, Republic of Korea.
| | - Jae-Hwan Nam
- Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.
- BK Plus Department of Biotechnology, The Catholic University of Korea, Bucheon, Republic of Korea.
| |
Collapse
|
4
|
Sohn HS, Choi JW, Jhun J, Kwon SP, Jung M, Yong S, Na HS, Kim JH, Cho ML, Kim BS. Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis. Sci Adv 2022; 8:eabo5284. [PMID: 36427299 PMCID: PMC9699678 DOI: 10.1126/sciadv.abo5284] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Local inflammation in the joint is considered to contribute to osteoarthritis (OA) progression. Here, we describe an immunomodulating nanoparticle for OA treatment. Intradermal injection of lipid nanoparticles (LNPs) loaded with type II collagen (Col II) and rapamycin (LNP-Col II-R) into OA mice effectively induced Col II-specific anti-inflammatory regulatory T cells, substantially increased anti-inflammatory cytokine expression, and reduced inflammatory immune cells and proinflammatory cytokine expression in the joints. Consequently, LNP-Col II-R injection inhibited chondrocyte apoptosis and cartilage matrix degradation and relieved pain, while injection of LNPs loaded with a control peptide and rapamycin did not induce these events. Adoptive transfer of CD4+CD25+ T cells isolated from LNP-Col II-R-injected mice suggested that Tregs induced by LNP-Col II-R injection were likely responsible for the therapeutic effects. Collectively, this study suggests nanoparticle-mediated immunomodulation in the joint as a simple and effective treatment for OA.
Collapse
Affiliation(s)
- Hee Su Sohn
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Jeong Won Choi
- The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - JooYeon Jhun
- The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Sangmin Yong
- Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul 08826, Republic of Korea
| | - Hyun Sik Na
- Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea
- Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Jin-Hong Kim
- Department of Biological Sciences, College of Natural Sciences, Seoul National University, Seoul 08826, Republic of Korea
| | - Mi-La Cho
- The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea
- Corresponding author. (M.-L.C.), (B.-S.K.)
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
- Institute of Chemical Processes, Institute of Engineering Research, BioMAX, Seoul National University, Seoul 08826, Republic of Korea
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea
- Corresponding author. (M.-L.C.), (B.-S.K.)
| |
Collapse
|
5
|
Kim C, Lee SG, Lim S, Jung M, Kwon SP, Hong J, Kang M, Sohn HS, Go S, Moon S, Lee SJ, Kim JS, Kim BS. A Senolytic-Eluting Coronary Stent for the Prevention of In-Stent Restenosis. ACS Biomater Sci Eng 2022; 8:1921-1929. [PMID: 35416659 DOI: 10.1021/acsbiomaterials.1c01611] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
The vast majority of drug-eluting stents (DES) elute either sirolimus or one of its analogues. While limus drugs stymie vascular smooth muscle cell (VSMC) proliferation to prevent in-stent restenosis, their antiproliferative nature is indiscriminate and limits healing of the endothelium in stented vessels, increasing the risk of late-stent thrombosis. Oxidative stress, which is associated with vascular injury from stent implantation, can induce VSMCs to undergo senescence, and senescent VSMCs can produce pro-inflammatory cytokines capable of inducing proliferation of neighboring nonsenescent VSMCs. We explored the potential of senolytic therapy, which involves the selective elimination of senescent cells, in the form of a senolytic-eluting stent (SES) for interventional cardiology. Oxidative stress was modeled in vitro by exposing VSMCs to H2O2, and H2O2-mediated senescence was evaluated by cytochemical staining of senescence-associated β-galactosidase activity and qRT-PCR. Quiescent VSMCs were then treated with the conditioned medium (CM) of H2O2-treated VSMCs. Proliferative effects of CM were analyzed by staining for proliferating cell nuclear antigen. Senolytic effects of the first-generation senolytic ABT263 were observed in vitro, and the effects of ABT263 on endothelial cells were also investigated through an in vitro re-endothelialization assay. SESs were prepared by dip coating. Iliofemoral arteries of hypercholesteremic rabbits were implanted with SES, everolimus-eluting stents (EESs), or bare-metal stents (BMSs), and the area of stenosis was measured 4 weeks post-implantation using optical coherence tomography. We found that a portion of H2O2-treated VSMCs underwent senescence, and that CM of H2O2-treated senescent VSMCs triggered the proliferation of quiescent VSMCs. ABT263 reverted H2O2-mediated senescence and the proliferative capacity of senescent VSMC CM. Unlike everolimus, ABT263 did not affect endothelial cell migration and/or proliferation. SES, but not EES, significantly reduced stenosis area in vivo compared with bare-metal stents (BMSs). This study shows the potential of SES as an alternative to current forms of DES.
Collapse
Affiliation(s)
- Cheesue Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Seul-Gee Lee
- Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
| | - Songhyun Lim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Jihye Hong
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Hee Su Sohn
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Seokhyeong Go
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Sangjun Moon
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Seung-Jun Lee
- Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
| | - Jung-Sun Kim
- Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.,Cardiology Division, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.,Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.,Institute of Chemical Processes, Institute of Engineering Research, and BioMAX, Seoul National University, Seoul 08826, Republic of Korea
| |
Collapse
|
6
|
Lee JR, Park BW, Park JH, Lim S, Kwon SP, Hwang JW, Kim H, Park HJ, Kim BS. Local delivery of a senolytic drug in ischemia and reperfusion-injured heart attenuates cardiac remodeling and restores impaired cardiac function. Acta Biomater 2021; 135:520-533. [PMID: 34454081 DOI: 10.1016/j.actbio.2021.08.028] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 08/17/2021] [Accepted: 08/19/2021] [Indexed: 12/15/2022]
Abstract
Myocardial ischemia-reperfusion (IR) generates stress-induced senescent cells (SISCs) that play an important role in the pathophysiology of adverse cardiac remodeling and heart failure via secretion of pro-inflammatory molecules and matrix-degrading proteases. Thus, removal of senescent cells using a senolytic drug could be a potentially effective treatment. However, clinical studies on cancer treatment with a senolytic drug have revealed that systemic administration of a senolytic drug often causes systemic toxicity. Herein we show for the first time that local delivery of a senolytic drug can effectively treat myocardial IR injury. We found that biodegradable poly(lactic-co-glycolic acid) nanoparticle-based local delivery of a senolytic drug (ABT263-PLGA) successfully eliminated SISCs in the IR-injured rat hearts without systemic toxicity. Consequently, the treatment ameliorated inflammatory responses and attenuated adverse remodeling. Surprisingly, the ABT263-PLGA treatment restored the cardiac function over time, whereas the cardiac function decreased over time in the no treatment group. Mechanistically, the ABT263-PLGA treatment not only markedly reduced the expression of pro-inflammatory molecules and matrix-degrading proteases, but also induced macrophage polarization from the inflammatory phase to the reparative phase via efferocytosis of apoptotic SISCs by macrophages. Therefore, the senolytic strategy with ABT263-PLGA in the early stage of myocardial IR injury may be an effective therapeutic option for myocardial infarction. STATEMENT OF SIGNIFICANCE: This study describes a local injection of senolytic drug-loaded nanoparticles that selectively kills stress-induced senescent cells (SISCs) in infarcted heart. Removal of SISCs decreases inflammatory cytokines and normal cell death. We firstly revealed that further efferocytosis of apoptotic senescent cells by macrophages restores cardiac function after myocardial ischemia-reperfusion injury. Importantly, a local injection of senolytic drug did not exhibit systemic toxicity, but a systemic injection did. Our findings not only spotlight the basic understanding of therapeutic potential of senolysis in infarcted myocardium, but also pave the way for the further application of senolytic drug for non-aging related diseases.
Collapse
Affiliation(s)
- Ju-Ro Lee
- Chemical and Biological Engineering, Seoul National University, Seoul 08826, South Korea
| | - Bong-Woo Park
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea; Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea
| | - Jae-Hyun Park
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea; Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea
| | - Songhyun Lim
- Chemical and Biological Engineering, Seoul National University, Seoul 08826, South Korea
| | - Sung Pil Kwon
- Chemical and Biological Engineering, Seoul National University, Seoul 08826, South Korea
| | - Ji-Won Hwang
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea; Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea
| | - Hyeok Kim
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea; Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea
| | - Hun-Jun Park
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, South Korea; Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Seoul 06591, South Korea; Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul 06591, South Korea.
| | - Byung-Soo Kim
- Chemical and Biological Engineering, Seoul National University, Seoul 08826, South Korea; Institute of Chemical Processes, Institute of Engineering Research, Seoul National University, Seoul 08826, South Korea.
| |
Collapse
|
7
|
Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, Koo S, Kwon SP, Moon S, Jung M, Hong J, Go S, Song SY, Choi JH, Hyeon T, Oh YK, Park HH, Kim BS. Nanocomplex-Mediated In Vivo Programming to Chimeric Antigen Receptor-M1 Macrophages for Cancer Therapy. Adv Mater 2021; 33:e2103258. [PMID: 34510559 DOI: 10.1002/adma.202103258] [Citation(s) in RCA: 59] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 08/06/2021] [Indexed: 06/13/2023]
Abstract
Chimeric antigen receptor-T (CAR-T) cell immunotherapy has shown impressive clinical outcomes for hematologic malignancies. However, its broader applications are challenged due to its complex ex vivo cell-manufacturing procedures and low therapeutic efficacy against solid tumors. The limited therapeutic effects are partially due to limited CAR-T cell infiltration to solid tumors and inactivation of CAR-T cells by the immunosuppressive tumor microenvironment. Here, a facile approach is presented to in vivo program macrophages, which can intrinsically penetrate solid tumors, into CAR-M1 macrophages displaying enhanced cancer-directed phagocytosis and anti-tumor activity. In vivo injected nanocomplexes of macrophage-targeting nanocarriers and CAR-interferon-γ-encoding plasmid DNA induce CAR-M1 macrophages that are capable of CAR-mediated cancer phagocytosis, anti-tumor immunomodulation, and inhibition of solid tumor growth. Together, this study describes an off-the-shelf CAR-macrophage therapy that is effective for solid tumors and avoids the complex and costly processes of ex vivo CAR-cell manufacturing.
Collapse
Affiliation(s)
- Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seong Ho Lee
- Department of Smart Health Science and Technology, Kangwon National University, Chuncheon, 24341, Republic of Korea
| | - Miji Kwon
- Department of Smart Health Science and Technology, Kangwon National University, Chuncheon, 24341, Republic of Korea
| | - Junho Byun
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea
| | - Dongyoon Kim
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea
| | - Cheesue Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Sagang Koo
- Center for Nanoparticle Research, Institute of Basic Science (IBS), Seoul, 08826, Republic of Korea
- School of Chemical and Biological Engineering, and Institute of Chemical Processes, Seoul National University, Seoul, 08826, Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Sangjun Moon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jihye Hong
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seokhyeong Go
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jae Hyun Choi
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea
| | - Taeghwan Hyeon
- Center for Nanoparticle Research, Institute of Basic Science (IBS), Seoul, 08826, Republic of Korea
- School of Chemical and Biological Engineering, and Institute of Chemical Processes, Seoul National University, Seoul, 08826, Republic of Korea
| | - Yu-Kyoung Oh
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea
| | - Hee Ho Park
- Department of Bioengineering, Hanyang University, Seoul, 04763, Republic of Korea
- Education and Research Group for Biopharmaceutical Innovation Leader, Hanyang University, Seoul, 04763, Republic of Korea
| | - Byung-Soo Kim
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
- Institute of Chemical Processes, Institute of Engineering Research, BioMAX, Seoul National University, Seoul, 08826, Republic of Korea
| |
Collapse
|
8
|
Kwon SP, Hwang BH, Park EH, Kim HY, Lee JR, Kang M, Song SY, Jung M, Sohn HS, Kim E, Kim CW, Lee KY, Oh GC, Choo E, Lim S, Chung Y, Chang K, Kim BS. Nanoparticle-Mediated Blocking of Excessive Inflammation for Prevention of Heart Failure Following Myocardial Infarction. Small 2021; 17:e2101207. [PMID: 34216428 DOI: 10.1002/smll.202101207] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 03/27/2021] [Indexed: 06/13/2023]
Abstract
Severe cardiac damage following myocardial infarction (MI) causes excessive inflammation, which sustains tissue damage and often induces adverse cardiac remodeling toward cardiac function impairment and heart failure. Timely resolution of post-MI inflammation may prevent cardiac remodeling and development of heart failure. Cell therapy approaches for MI are time-consuming and costly, and have shown marginal efficacy in clinical trials. Here, nanoparticles targeting the immune system to attenuate excessive inflammation in infarcted myocardium are presented. Liposomal nanoparticles loaded with MI antigens and rapamycin (L-Ag/R) enable effective induction of tolerogenic dendritic cells presenting the antigens and subsequent induction of antigen-specific regulatory T cells (Tregs). Impressively, intradermal injection of L-Ag/R into acute MI mice attenuates inflammation in the myocardium by inducing Tregs and an inflammatory-to-reparative macrophage polarization, inhibits adverse cardiac remodeling, and improves cardiac function. Nanoparticle-mediated blocking of excessive inflammation in infarcted myocardium may be an effective intervention to prevent the development of post-MI heart failure.
Collapse
Affiliation(s)
- Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Byung-Hee Hwang
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Eun-Hye Park
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Han Young Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Ju-Ro Lee
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Hee Su Sohn
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Eunmin Kim
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Chan Woo Kim
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Kwan Yong Lee
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Gyu Chul Oh
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Eunho Choo
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Songhyun Lim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Yeonseok Chung
- Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea
| | - Kiyuk Chang
- Cardiovascular Research Institute for Intractable Disease, Division of Cardiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
- Institute of Chemical Processes, Institute of Engineering Research, BioMAX, Seoul National University, Seoul, 08826, Republic of Korea
| |
Collapse
|
9
|
Kwon SP, Song SY, Yoo J, Kim HY, Lee JR, Kang M, Sohn HS, Go S, Jung M, Hong J, Lim S, Kim C, Moon S, Char K, Kim BS. Multilayered Cell Sheets of Cardiac Reprogrammed Cells for the Evaluation of Drug Cytotoxicity. Tissue Eng Regen Med 2021; 18:807-818. [PMID: 34251653 DOI: 10.1007/s13770-021-00363-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Revised: 06/05/2021] [Accepted: 06/10/2021] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Various cell-culture systems have been used to evaluate drug toxicity in vitro. However, factors that affect cytotoxicity outcomes in drug toxicity evaluation systems remain elusive. In this study, we used multilayered sheets of cardiac-mimetic cells, which were reprogrammed from human fibroblasts, to investigate the effects of the layer number on drug cytotoxicity outcomes. METHODS Cell sheets of cardiac-mimetic cells were fabricated by reprogramming of human fibroblasts into cardiac-mimetic cells via coculture with cardiac cells and electric stimulation, as previously described. Double-layered cell sheets were prepared by stacking the cell sheets. The mono- and double-layered cell sheets were treated with 5-fluorouracil (5-FU), an anticancer drug, in vitro. Subsequently, apoptosis and lipid peroxidation were analyzed. Furthermore, effects of cardiac-mimetic cell density on cytotoxicity outcomes were evaluated by culturing cells in monolayer at various cell densities. RESULTS The double-layered cell sheets exhibited lower cytotoxicity in terms of apoptosis and lipid peroxidation than the mono-layered sheets at the same 5-FU dose. In addition, the double-layered cell sheets showed better preservation of mitochondrial function and plasma membrane integrity than the monolayer sheets. The lower cytotoxicity outcomes in the double-layered cell sheets may be due to the higher intercellular interactions, as the cytotoxicity of 5-FU decreased with cell density in monolayer cultures of cardiac-mimetic cells. CONCLUSION The layer number of cardiac-mimetic cell sheets affects drug cytotoxicity outcomes in drug toxicity tests. The in vitro cellular configuration that more closely mimics the in vivo configuration in the evaluation systems seems to exhibit lower cytotoxicity in response to drug.
Collapse
Affiliation(s)
- Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jin Yoo
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Han Young Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Ju-Ro Lee
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Hee Su Sohn
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seokhyoung Go
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jihye Hong
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Songhyun Lim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Cheesue Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Sangjun Moon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Kookheon Char
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea. .,Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea. .,Institute of Chemical Processes, Institute of Engineering Research, BioMAX, Seoul National University, Seoul, 08826, Republic of Korea.
| |
Collapse
|
10
|
Go S, Kang M, Kwon SP, Jung M, Jeon OH, Kim B. The Senolytic Drug JQ1 Removes Senescent Cells via Ferroptosis. Tissue Eng Regen Med 2021; 18:841-850. [PMID: 34003467 PMCID: PMC8440740 DOI: 10.1007/s13770-021-00346-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 04/14/2021] [Accepted: 04/19/2021] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Ferroptosis is an iron-dependent, non-apoptotic programmed cell death. Cellular senescence contributes to aging and various age-related diseases through the expression of a senescence-associated secretory phenotype (SASP). Senescent cells are often resistant to ferroptosis via increased ferritin and impaired ferritinophagy. In this study, we investigated whether treatment with JQ1 could remove senescent cells by inducing ferroptosis. METHODS Senescence of human dermal fibroblasts was induced in vitro by treating the cells with bleomycin. The senolytic effects of JQ1 were evaluated using a SA-β gal assay, annexin V analysis, cell counting kit-8 assay, and qRT-PCR. Ferroptosis following JQ1 treatment was evaluated with qRT-PCR and BODIPY staining. RESULTS At a certain range of JQ1 concentrations, JQ1 treatment reduced the viability of bleomycin-treated cells (senescent cells) but did not reduce that of untreated cells (non-senescent cells), indicating that JQ1 treatment can selectively eliminate senescent cells. JQ1 treatment also decreased SASP expression only in senescent cells. Subsequently, JQ1 treatment reduced the expression of ferroptosis-resistance genes in senescent cells. JQ1 treatment induced lipid peroxidation in senescent cells but not in non-senescent cells. CONCLUSION The data indicate that JQ1 can eliminate senescent cells via ferroptosis. This study suggests ferroptosis as a new mechanism of senolytic therapy.
Collapse
Affiliation(s)
- Seokhyeong Go
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826 Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826 Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826 Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826 Republic of Korea
| | - Ok Hee Jeon
- Department of Biomedical Sciences, BK21 Graduate Program, Korea University of College of Medicine, Seoul, 02841, Republic of Korea.
| | - Byung‐Soo Kim
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826 Republic of Korea ,School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826 Republic of Korea ,Institute of Chemical Processes, Institute of Engineering Research, and BioMAX, Seoul National University, Seoul, 08826 Republic of Korea
| |
Collapse
|
11
|
Kang M, Hong J, Jung M, Kwon SP, Song SY, Kim HY, Lee JR, Kang S, Han J, Koo JH, Ryu JH, Lim S, Sohn HS, Choi JM, Doh J, Kim BS. T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy. Adv Mater 2020; 32:e2003368. [PMID: 32812291 DOI: 10.1002/adma.202003368] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2020] [Revised: 06/26/2020] [Indexed: 06/11/2023]
Abstract
Cancer immunotherapies, including adoptive T cell transfer and immune checkpoint blockades, have recently shown considerable success in cancer treatment. Nevertheless, transferred T cells often become exhausted because of the immunosuppressive tumor microenvironment. Immune checkpoint blockades, in contrast, can reinvigorate the exhausted T cells; however, the therapeutic efficacy is modest in 70-80% of patients. To address some of the challenges faced by the current cancer treatments, here T-cell-membrane-coated nanoparticles (TCMNPs) are developed for cancer immunotherapy. Similar to cytotoxic T cells, TCMNPs can be targeted at tumors via T-cell-membrane-originated proteins and kill cancer cells by releasing anticancer molecules and inducing Fas-ligand-mediated apoptosis. Unlike cytotoxic T cells, TCMNPs are resistant to immunosuppressive molecules (e.g., transforming growth factor-β1 (TGF-β1)) and programmed death-ligand 1 (PD-L1) of cancer cells by scavenging TGF-β1 and PD-L1. Indeed, TCMNPs exhibit higher therapeutic efficacy than an immune checkpoint blockade in melanoma treatment. Furthermore, the anti-tumoral actions of TCMNPs are also demonstrated in the treatment of lung cancer in an antigen-nonspecific manner. Taken together, TCMNPs have a potential to improve the current cancer immunotherapy.
Collapse
Affiliation(s)
- Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jihye Hong
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Han Young Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Ju-Ro Lee
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Seokyung Kang
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Jin Han
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Ja-Hyun Koo
- Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, 04763, Republic of Korea
- Research Institute for Natural Sciences, Hanyang University, Seoul, 04763, Republic of Korea
| | - Ju Hee Ryu
- Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea
| | - Songhyun Lim
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Hee Su Sohn
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Je-Min Choi
- Department of Life Science, College of Natural Sciences, Hanyang University, Seoul, 04763, Republic of Korea
- Research Institute for Natural Sciences, Hanyang University, Seoul, 04763, Republic of Korea
- Research Institute for Convergence of Basic Sciences, Hanyang University, Seoul, 04763, Republic of Korea
| | - Junsang Doh
- Department of Materials Science and Engineering, Seoul National University, Seoul, 08826, Republic of Korea
| | - Byung-Soo Kim
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul, 08826, Republic of Korea
- School of Chemical and Biological Engineering, Seoul National University, Seoul, 08826, Republic of Korea
- Institute of Chemical Processes, Institute of Engineering Research, BioMAX, Seoul National University, Seoul, 08826, Republic of Korea
| |
Collapse
|
12
|
Lee JR, Park BW, Kim J, Choo YW, Kim HY, Yoon JK, Kim H, Hwang JW, Kang M, Kwon SP, Song SY, Ko IO, Park JA, Ban K, Hyeon T, Park HJ, Kim BS. Nanovesicles derived from iron oxide nanoparticles-incorporated mesenchymal stem cells for cardiac repair. Sci Adv 2020; 6:eaaz0952. [PMID: 32494669 PMCID: PMC7195131 DOI: 10.1126/sciadv.aaz0952] [Citation(s) in RCA: 99] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2019] [Accepted: 02/12/2020] [Indexed: 05/18/2023]
Abstract
Because of poor engraftment and safety concerns regarding mesenchymal stem cell (MSC) therapy, MSC-derived exosomes have emerged as an alternative cell-free therapy for myocardial infarction (MI). However, the diffusion of exosomes out of the infarcted heart following injection and the low productivity limit the potential of clinical applications. Here, we developed exosome-mimetic extracellular nanovesicles (NVs) derived from iron oxide nanoparticles (IONPs)-incorporated MSCs (IONP-MSCs). The retention of injected IONP-MSC-derived NVs (IONP-NVs) within the infarcted heart was markedly augmented by magnetic guidance. Furthermore, IONPs significantly increased the levels of therapeutic molecules in IONP-MSCs and IONP-NVs, which can reduce the concern of low exosome productivity. The injection of IONP-NVs into the infarcted heart and magnetic guidance induced an early shift from the inflammation phase to the reparative phase, reduced apoptosis and fibrosis, and enhanced angiogenesis and cardiac function recovery. This approach can enhance the therapeutic potency of an MSC-derived NV therapy.
Collapse
Affiliation(s)
- Ju-Ro Lee
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Bong-Woo Park
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Jonghoon Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
- Center for Nanoparticle Research, Institute of Basic Science (IBS), Seoul 08826, Republic of Korea
| | - Yeon Woong Choo
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Han Young Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Jeong-Kee Yoon
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Hyeok Kim
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul 06591, Republic of Korea
| | - Ji-Won Hwang
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul 06591, Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
| | - In Ok Ko
- Division of Applied RI, Korea Institute Radiological and Medical Sciences, Seoul 01812, Republic of Korea
| | - Ji-Ae Park
- Division of Applied RI, Korea Institute Radiological and Medical Sciences, Seoul 01812, Republic of Korea
| | - Kiwon Ban
- Department of Biomedical Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong
| | - Taeghwan Hyeon
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
- Center for Nanoparticle Research, Institute of Basic Science (IBS), Seoul 08826, Republic of Korea
- Institute of Chemical Processes, Institute of Engineering Research, BIOMAX, Seoul National University, Seoul 08826, Republic of Korea
| | - Hun-Jun Park
- Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Seoul 06591, Republic of Korea
- Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Corresponding author. (B.-S.K.); (H.-J.P.)
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea
- Institute of Chemical Processes, Institute of Engineering Research, BIOMAX, Seoul National University, Seoul 08826, Republic of Korea
- Corresponding author. (B.-S.K.); (H.-J.P.)
| |
Collapse
|
13
|
Lee HS, Park HY, Kwon SP, Kim B, Lee Y, Kim S, Shin KO, Park K. NADPH Oxidase-Mediated Activation of Neutral Sphingomyelinase Is Responsible for Diesel Particulate Extract-Induced Keratinocyte Apoptosis. Int J Mol Sci 2020; 21:ijms21031001. [PMID: 32028642 PMCID: PMC7037446 DOI: 10.3390/ijms21031001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 01/27/2020] [Accepted: 02/01/2020] [Indexed: 12/15/2022] Open
Abstract
Human epidermis is positioned at the interface with the external environment, protecting our bodies against external challenges, including air pollutants. Emerging evidence suggests that diesel particulate extract (DPE), a major component of air pollution, leads to impairment of diverse cellular functions in keratinocytes (KC). In this study, we investigated the cellular mechanism underlying DPE-induced KC apoptosis. We first addressed cell death occurring in KC exposed to DPE, paralleled by increased activation of NADPH oxidases (NOXs) and subsequent ROS generation. Blockade of NOX activation with a specific inhibitor attenuated the expected DPE-induced KC apoptosis. In contrast, pre-treatment with a specific inhibitor of reactive oxygen species (ROS) generation did not reverse DPE/NOX-mediated increase in KC apoptosis. We next noted that NOX-mediated KC apoptosis is mainly attributable to neutral sphingomyelinase (SMase)-mediated stimulation of ceramides, which is a well-known pro-apoptotic lipid. Moreover, we found that inhibition of NOX activation significantly attenuated DPE-mediated increase in the ratio of ceramide to its key metabolite sphingosine-1-phosphate (S1P), an important determinant of cell fate. Together, these results suggest that activation of neutral SMase serves as a key downstream signal for the DPE/NOX activation-mediated alteration in ceramide and S1P productions, and subsequent KC apoptosis.
Collapse
Affiliation(s)
- Hyun-Seok Lee
- Research & Development Center, Chungdam CDC JNPharm LLC., Chuncheon 24232, Korea
| | - Hye Yoon Park
- Biological and Genetic Resources Assessment Division, National Institute of Biological Resources, Incheon 22689, Korea
| | - Sung Pil Kwon
- Research & Development Center, Chungdam CDC JNPharm LLC., Chuncheon 24232, Korea
| | - Bogyeong Kim
- Department of Food Science & Nutrition, and Convergence Program of Material Science for Medicine and Pharmaceutics, Hallym University, Chuncheon 24252, Korea
- Korean Institute of Nutrition, Hallym University, Chuncheon 24252, Korea
| | - Yerin Lee
- Department of Food Science & Nutrition, and Convergence Program of Material Science for Medicine and Pharmaceutics, Hallym University, Chuncheon 24252, Korea
- Korean Institute of Nutrition, Hallym University, Chuncheon 24252, Korea
| | - Seongeun Kim
- Department of Food Science & Nutrition, and Convergence Program of Material Science for Medicine and Pharmaceutics, Hallym University, Chuncheon 24252, Korea
- Korean Institute of Nutrition, Hallym University, Chuncheon 24252, Korea
| | - Kyong-Oh Shin
- Department of Food Science & Nutrition, and Convergence Program of Material Science for Medicine and Pharmaceutics, Hallym University, Chuncheon 24252, Korea
- Korean Institute of Nutrition, Hallym University, Chuncheon 24252, Korea
- Correspondences: (K.-O.S.); (K.P.); Tel.: +82-33-248-2141 (K.-O.S.); +82-33-248-2131 (K.P.)
| | - Kyungho Park
- Department of Food Science & Nutrition, and Convergence Program of Material Science for Medicine and Pharmaceutics, Hallym University, Chuncheon 24252, Korea
- Korean Institute of Nutrition, Hallym University, Chuncheon 24252, Korea
- Correspondences: (K.-O.S.); (K.P.); Tel.: +82-33-248-2141 (K.-O.S.); +82-33-248-2131 (K.P.)
| |
Collapse
|
14
|
Song SY, Kim H, Yoo J, Kwon SP, Park BW, Kim JJ, Ban K, Char K, Park HJ, Kim BS. Prevascularized, multiple-layered cell sheets of direct cardiac reprogrammed cells for cardiac repair. Biomater Sci 2020; 8:4508-4520. [DOI: 10.1039/d0bm00701c] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We developed cardiac-reprogrammed cell sheets via cardiac-mimetic cell culture system with biodegradable PLGA membrane. The prevascularized, multiple-layered cell sheets prevented heart failure after myocardial infarction.
Collapse
Affiliation(s)
- Seuk Young Song
- School of Chemical and Biological Engineering
- Seoul National University
- Seoul
- Republic of Korea
| | - Hyeok Kim
- Department of Medical Life Science
- College of Medicine
- The Catholic University of Korea
- Seoul
- Republic of Korea
| | - Jin Yoo
- School of Chemical and Biological Engineering
- Seoul National University
- Seoul
- Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering
- Seoul National University
- Seoul
- Republic of Korea
| | - Bong Woo Park
- Department of Medical Life Science
- College of Medicine
- The Catholic University of Korea
- Seoul
- Republic of Korea
| | - Jin-ju Kim
- Department of Medical Life Science
- College of Medicine
- The Catholic University of Korea
- Seoul
- Republic of Korea
| | - Kiwon Ban
- Department of Biomedical Sciences
- City University of Hong Kong
- Kowloon Tong
- Hong Kong
| | - Kookheon Char
- School of Chemical and Biological Engineering
- Seoul National University
- Seoul
- Republic of Korea
| | - Hun-Jun Park
- Department of Medical Life Science
- College of Medicine
- The Catholic University of Korea
- Seoul
- Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering
- Seoul National University
- Seoul
- Republic of Korea
- Institute of Chemical Processes
| |
Collapse
|
15
|
Kim HY, Kang M, Choo YW, Go SH, Kwon SP, Song SY, Sohn HS, Hong J, Kim BS. Immunomodulatory Lipocomplex Functionalized with Photosensitizer-Embedded Cancer Cell Membrane Inhibits Tumor Growth and Metastasis. Nano Lett 2019; 19:5185-5193. [PMID: 31298024 DOI: 10.1021/acs.nanolett.9b01571] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Liposomes are clinically used as drug carriers for cancer therapy; however, unwanted leakage of the encapsulated anticancer drug and poor tumor-targeting efficiency of liposomes may generate toxic side effects on healthy cells and lead to failure of tumor eradication. To overcome these limitations, we functionalized liposomes with a photosensitizer (KillerRed, KR)-embedded cancer cell membrane (CCM). A lipid adjuvant was also embedded in the lipocomplex to promote the anticancer immune response. KR proteins were expressed on CCM and did not leak from the lipocomplex. Owing to the homotypic affinity of the CCM for the source cancer cells, the lipocomplex exhibited a 3.3-fold higher cancer-targeting efficiency in vivo than a control liposome. The liposome functionalized with KR-embedded CCM and lipid adjuvant generated cytotoxic reactive oxygen species in photodynamic therapy and effectively induced anticancer immune responses, inhibiting primary tumor growth and lung metastasis in homotypic tumor-bearing mice. Taken together, the lipocomplex technology may improve liposome-based cancer therapy.
Collapse
Affiliation(s)
- Han Young Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program of Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Yeon Woong Choo
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Seok-Hyeong Go
- Interdisciplinary Program of Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Hee Su Sohn
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Jihye Hong
- Interdisciplinary Program of Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
- Interdisciplinary Program of Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
- Institute of Chemical Processes , Seoul National University , Seoul 08826 , Republic of Korea
| |
Collapse
|
16
|
Choo YW, Kang M, Kim HY, Han J, Kang S, Lee JR, Jeong GJ, Kwon SP, Song SY, Go S, Jung M, Hong J, Kim BS. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors. ACS Nano 2018; 12:8977-8993. [PMID: 30133260 DOI: 10.1021/acsnano.8b02446] [Citation(s) in RCA: 257] [Impact Index Per Article: 42.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Cancer immunotherapy modulates immune cells to induce antitumor immune responses. Tumors employ immune checkpoints to evade immune cell attacks. Immune checkpoint inhibitors such as anti-PD-L1 antibody (aPD-L1), which is being used clinically for cancer treatments, can block immune checkpoints so that the immune system can attack tumors. However, immune checkpoint inhibitor therapy may be hampered by polarization of macrophages within the tumor microenvironment (TME) into M2 tumor-associated macrophages (TAMs), which suppress antitumor immune responses and promote tumor growth by releasing anti-inflammatory cytokines and angiogenic factors. In this study, we used exosome-mimetic nanovesicles derived from M1 macrophages (M1NVs) to repolarize M2 TAMs to M1 macrophages that release pro-inflammatory cytokines and induce antitumor immune responses and investigated whether the macrophage repolarization can potentiate the anticancer efficacy of aPD-L1. M1NV treatment induced successful polarization of M2 macrophages to M1 macrophages in vitro and in vivo. Intravenous injection of M1NVs into tumor-bearing mice suppressed tumor growth. Importantly, injection of a combination of M1NVs and aPD-L1 further reduced the tumor size, compared to the injection of either M1NVs or aPD-L1 alone. Thus, our study indicates that M1NV injection can repolarize M2 TAMs to M1 macrophages and potentiate antitumor efficacy of the checkpoint inhibitor therapy.
Collapse
Affiliation(s)
- Yeon Woong Choo
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program for Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Han Young Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Jin Han
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Seokyung Kang
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Ju-Ro Lee
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Gun-Jae Jeong
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Seokhyeong Go
- Interdisciplinary Program for Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Mungyo Jung
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Jihye Hong
- Interdisciplinary Program for Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul 08826 , Republic of Korea
- Interdisciplinary Program for Bioengineering , Seoul National University , Seoul 08826 , Republic of Korea
- Institute of Chemical Processes , Seoul National University , Seoul 08826 , Republic of Korea
| |
Collapse
|
17
|
Kim HY, Kumar H, Jo MJ, Kim J, Yoon JK, Lee JR, Kang M, Choo YW, Song SY, Kwon SP, Hyeon T, Han IB, Kim BS. Therapeutic Efficacy-Potentiated and Diseased Organ-Targeting Nanovesicles Derived from Mesenchymal Stem Cells for Spinal Cord Injury Treatment. Nano Lett 2018; 18:4965-4975. [PMID: 29995418 DOI: 10.1021/acs.nanolett.8b01816] [Citation(s) in RCA: 119] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Human mesenchymal stem cell (hMSC)-derived exosomes have been spotlighted as a promising therapeutic agent for cell-free regenerative medicine. However, poor organ-targeting ability and insufficient therapeutic efficacy of systemically injected hMSC-exosomes were identified as critical limitations for their further applications. Therefore, in this study we fabricated iron oxide nanoparticle (IONP)-incorporated exosome-mimetic nanovesicles (NV-IONP) from IONP-treated hMSCs and evaluated their therapeutic efficacy in a clinically relevant model for spinal cord injury. Compared to exosome-mimetic nanovesicles (NV) prepared from untreated hMSCs, NV-IONP not only contained IONPs which act as a magnet-guided navigation tool but also carried greater amounts of therapeutic growth factors that can be delivered to the target cells. The increased amounts of therapeutic growth factors inside NV-IONP were attributed to IONPs that are slowly ionized to iron ions which activate the JNK and c-Jun signaling cascades in hMSCs. In vivo systemic injection of NV-IONP with magnetic guidance significantly increased the amount of NV-IONP accumulating in the injured spinal cord. Accumulated NV-IONP enhanced blood vessel formation, attenuated inflammation and apoptosis in the injured spinal cord, and consequently improved spinal cord function. Taken together, these findings highlight the development of therapeutic efficacy-potentiated extracellular nanovesicles and demonstrate their feasibility for repairing injured spinal cord.
Collapse
Affiliation(s)
- Han Young Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Hemant Kumar
- Department of Neurosurgery , CHA University , CHA Bundang Medical Center, Seongnam-si , 13488 , Republic of Korea
| | - Min-Jae Jo
- Department of Neurosurgery , CHA University , CHA Bundang Medical Center, Seongnam-si , 13488 , Republic of Korea
| | - Jonghoon Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
- Center for Nanoparticle Research , Institute for Basic Science (IBS) , Seoul 151-744 , Republic of Korea
| | - Jeong-Kee Yoon
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Ju-Ro Lee
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Mikyung Kang
- Interdisciplinary Program of Bioengineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Yeon Woong Choo
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Seuk Young Song
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Sung Pil Kwon
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
| | - Taeghwan Hyeon
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
- Center for Nanoparticle Research , Institute for Basic Science (IBS) , Seoul 151-744 , Republic of Korea
| | - In-Bo Han
- Department of Neurosurgery , CHA University , CHA Bundang Medical Center, Seongnam-si , 13488 , Republic of Korea
| | - Byung-Soo Kim
- School of Chemical and Biological Engineering , Seoul National University , Seoul , 08826 , Republic of Korea
- Interdisciplinary Program of Bioengineering , Seoul National University , Seoul , 08826 , Republic of Korea
- Institute of Chemical Processes , Seoul National University , Seoul , 08826 , Republic of Korea
| |
Collapse
|
18
|
|
19
|
Kwon SP, Chung Y, Yang JM, Kim MH. Persistent chemicals in birds and herbs in Korea. Yonsei Med J 1976; 17:21-9. [PMID: 1036345 DOI: 10.3349/ymj.1976.17.1.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
20
|
Kwon SP. A study on the isozymic alterations of lactic dehydrogenase in the tissues of rats following sulfur dioxide exposure. Yonsei Med J 1969; 10:37-47. [PMID: 5374817 DOI: 10.3349/ymj.1969.10.1.37] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
|
21
|
|